SV2003000741A - Compuesto lactamico x-13170 - Google Patents

Compuesto lactamico x-13170

Info

Publication number
SV2003000741A
SV2003000741A SV2001000741A SV2001000741A SV2003000741A SV 2003000741 A SV2003000741 A SV 2003000741A SV 2001000741 A SV2001000741 A SV 2001000741A SV 2001000741 A SV2001000741 A SV 2001000741A SV 2003000741 A SV2003000741 A SV 2003000741A
Authority
SV
El Salvador
Prior art keywords
lactamic
compound
procedures
prepare
methyl
Prior art date
Application number
SV2001000741A
Other languages
English (en)
Spanish (es)
Inventor
Thomas Mitchell Koenig
James Edmund Audia
David Mitchell
Stacey Leigh Mcdaniel
Lynne Ann Buccilli
Gary Lowell Engel
James Abraham Aikins
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of SV2003000741A publication Critical patent/SV2003000741A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16—Benzazepines; Hydrogenated benzazepines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Cephalosporin Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyrrole Compounds (AREA)
SV2001000741A 2000-11-17 2001-11-16 Compuesto lactamico x-13170 SV2003000741A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US24965600P 2000-11-17 2000-11-17

Publications (1)

Publication Number Publication Date
SV2003000741A true SV2003000741A (es) 2003-01-13

Family

ID=22944436

Family Applications (1)

Application Number Title Priority Date Filing Date
SV2001000741A SV2003000741A (es) 2000-11-17 2001-11-16 Compuesto lactamico x-13170

Country Status (33)

Country Link
US (1) US20040248878A1 (enExample)
EP (1) EP1353910B1 (enExample)
JP (1) JP4116431B2 (enExample)
KR (1) KR20030045194A (enExample)
CN (2) CN101624372A (enExample)
AR (1) AR031356A1 (enExample)
AT (1) ATE362919T1 (enExample)
AU (2) AU2002224321B2 (enExample)
BR (1) BR0115424A (enExample)
CA (1) CA2425497C (enExample)
CY (1) CY1106682T1 (enExample)
CZ (1) CZ20031340A3 (enExample)
DE (1) DE60128587T2 (enExample)
DK (1) DK1353910T3 (enExample)
DZ (1) DZ3454A1 (enExample)
EA (1) EA006919B1 (enExample)
EC (1) ECSP034598A (enExample)
ES (1) ES2286162T3 (enExample)
HR (1) HRP20030385A2 (enExample)
HU (1) HUP0301862A3 (enExample)
IL (1) IL155275A0 (enExample)
MX (1) MXPA03004250A (enExample)
MY (1) MY141607A (enExample)
NO (1) NO325217B1 (enExample)
PE (1) PE20020798A1 (enExample)
PL (1) PL211018B1 (enExample)
PT (1) PT1353910E (enExample)
SK (1) SK287794B6 (enExample)
SV (1) SV2003000741A (enExample)
TW (1) TWI235151B (enExample)
UA (1) UA77165C2 (enExample)
WO (1) WO2002040451A2 (enExample)
ZA (1) ZA200303411B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA74849C2 (en) * 2000-11-17 2006-02-15 Lilly Co Eli Lactam
EP2186516B1 (en) 2002-12-20 2013-01-16 Glaxo Group Limited Novel benzazepine derivative
NZ540612A (en) 2003-01-14 2008-02-29 Arena Pharm Inc 1,2,3-Trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia
AR045047A1 (es) 2003-07-11 2005-10-12 Arena Pharm Inc Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
JP5039543B2 (ja) 2005-04-08 2012-10-03 第一三共株式会社 ピリジルメチルスルホン誘導体
WO2007088878A1 (ja) 2006-01-31 2007-08-09 Api Corporation ベンゾアゼピノン類の製造方法
TW200920362A (en) 2007-09-11 2009-05-16 Daiichi Sankyo Co Ltd Alkylsulfone derivatives
FR2932800B1 (fr) * 2008-06-20 2015-02-20 Servier Lab Nouveau procede de synthese de la 7,8-dimethoxy-1,3-dihydro- 2h-3-benzazepin-2-one, et application a la synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable
CN103221410B (zh) 2010-09-22 2017-09-15 艾尼纳制药公司 Gpr119受体调节剂和对与其相关的障碍的治疗
KR101899014B1 (ko) 2012-01-06 2018-09-17 삼성전자주식회사 비엘디씨 모터의 제어 장치 및 그 방법
CN102690231B (zh) * 2012-04-11 2014-07-09 南京友杰医药科技有限公司 治疗阿尔茨海默病潜在药物司马西特的合成方法
US20160067306A1 (en) 2013-04-19 2016-03-10 National University Corporation Hokkaido University Treatment agent for cognitive impairment induced by amyloid beta-protein, therapeutic agent for alzheimer's disease, and treatment method and pathological analysis method related to these
EP4445956A3 (en) 2015-01-06 2024-12-04 Arena Pharmaceuticals, Inc. Compound for use in treating conditions related to the s1p1 receptor
PL3310760T3 (pl) 2015-06-22 2023-03-06 Arena Pharmaceuticals, Inc. Krystaliczna sól L-argininy kwasu (R)-2-(7-(4-cyklopentylo-3-(trifluorometylo)benzyloksy)- 1,2,3,4-tetrahydrocyklo-penta[b]indol-3-ilo)octowego do zastosowania w zaburzeniach związanych z receptorem S1P1
MA47504A (fr) 2017-02-16 2019-12-25 Arena Pharm Inc Composés et méthodes de traitement de l'angiocholite biliaire primitive
ES2987794T3 (es) 2018-06-06 2024-11-18 Arena Pharm Inc Procedimientos de tratamiento de afecciones relacionadas con el receptor S1P1
AU2021244215A1 (en) 2020-03-26 2022-10-13 Seagen Inc. Methods of treating multiple myeloma

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT951466E (pt) * 1996-12-23 2009-04-09 Lilly Co Eli Compostos cicloalquilo, lactama, lactona e relacionados, composições farmacêuticas compreendendo os mesmos, e métodos para a inibição da libertação do péptido β-amilóide e/ou da sua síntese pela utilização de tais compostos
AU4707999A (en) * 1998-06-22 2000-01-10 Elan Pharmaceuticals, Inc. Compounds for inhibiting beta-amyloid peptide release and/or its synthesis
CA2390376A1 (en) * 1999-11-09 2001-05-17 William Leonard Scott .beta.-aminoacid compounds useful for inhibiting .beta.-amyloid peptide release and/or its synthesis

Also Published As

Publication number Publication date
AR031356A1 (es) 2003-09-17
TWI235151B (en) 2005-07-01
CN100516047C (zh) 2009-07-22
ZA200303411B (en) 2004-08-02
HUP0301862A2 (hu) 2003-09-29
HRP20030385A2 (en) 2003-08-31
EA200300579A1 (ru) 2003-12-25
EP1353910A2 (en) 2003-10-22
UA77165C2 (en) 2006-11-15
PL211018B1 (pl) 2012-03-30
DE60128587D1 (de) 2007-07-05
CA2425497A1 (en) 2002-05-23
KR20030045194A (ko) 2003-06-09
CA2425497C (en) 2010-08-17
CY1106682T1 (el) 2012-05-23
ECSP034598A (es) 2003-06-25
BR0115424A (pt) 2003-10-21
WO2002040451A3 (en) 2003-08-28
AU2002224321B2 (en) 2006-10-19
EP1353910B1 (en) 2007-05-23
HUP0301862A3 (en) 2007-09-28
AU2432102A (en) 2002-05-27
DZ3454A1 (fr) 2002-05-23
US20040248878A1 (en) 2004-12-09
SK5432003A3 (en) 2004-09-08
DE60128587T2 (de) 2008-01-31
CN101624372A (zh) 2010-01-13
NO20032215D0 (no) 2003-05-15
PT1353910E (pt) 2007-08-20
DK1353910T3 (da) 2007-09-10
IL155275A0 (en) 2003-11-23
JP2004521084A (ja) 2004-07-15
ES2286162T3 (es) 2007-12-01
MY141607A (en) 2010-05-31
WO2002040451A2 (en) 2002-05-23
CZ20031340A3 (cs) 2004-06-16
JP4116431B2 (ja) 2008-07-09
SK287794B6 (sk) 2011-10-04
CN1575282A (zh) 2005-02-02
ATE362919T1 (de) 2007-06-15
NO325217B1 (no) 2008-02-25
NO20032215L (no) 2003-07-16
PL360991A1 (en) 2004-09-20
MXPA03004250A (es) 2003-09-22
EA006919B1 (ru) 2006-04-28
PE20020798A1 (es) 2002-09-06

Similar Documents

Publication Publication Date Title
SV2003000741A (es) Compuesto lactamico x-13170
CR7182A (es) Benzoilsufanamidas y sulfonilbenzamidinas que se usan como agentes antitumorales
AR026163A1 (es) Utilizacion de retigabina para el tratamiento de dolores neuropaticos
HN1999000089A (es) Formulaciones de ziprasidona
DE60135919D1 (de) Farnesyl transferase-hemmende 6-heterocyclylmethyl-chinolin und chinazol-derivate
CY1106132T1 (el) Παραγωγα πιπepιδινης ως αναστολεις καναλιου καλιου
SE0000540D0 (sv) New compounds
BRPI0411528A (pt) uso de isomalte como prebiótico
PA8583401A1 (es) Nuevos compuestos de triazol como inhibidores del factor de crecimiento transformante (tgf)
BR0113798A (pt) Derivados de resorcinol
SE0301653D0 (sv) Novel compounds
BR0211761A (pt) depsipeptìdeos e processos para preparar os mesmos
SE9901077D0 (sv) Novel use
GT200600199A (es) Diarilsulfonas sulfonamidas y su uso
CY1105009T1 (el) Συνθεση καχαλαλιδης f
DK1105114T3 (da) Nimesulidholdige topiske farmaceutiske sammensætninger
SE9801494D0 (sv) Novel use
CR7956A (es) Oxazolidinonas de indolona antibacterial intermedios para su preparacion y composiciones farmaceuticas que contienen los mismos
GT200000035AA (es) Derivados de resorcinol, (solicitud fraccionaria no. 1 derivada de la patente pi-2000-0035)
UA88867C2 (ru) Композиция, которая содержит модафинил, и ее применение
BRPI0416678A (pt) pirazolpirimidinas
DK1492501T3 (da) Fremgangsmåder med anvendelse af lamellare legemer til terapeutiske formål
HN2000000056A (es) Nuevas formas cristalinas de un antibiotico macrolido
SV2004001370A (es) Compuestos basicos lineales que tienen actividad antagonista de nk-2 y sus formulaciones
PA8595701A1 (es) Agentes de despigmentacion